Dr. Mark L. Hayman focuses his practice on patent counseling and procurement in the areas of biotechnology, pharmaceuticals, and nanotechnology. Mark earned his Ph.D. in microbiology from the University at Buffalo in 2000. His graduate research focused on identifying protein factors that are involved in an RNA editing process unique to trypanosome parasites and related organisms.
Mark is well versed in building patent portfolios to optimize product exclusivity positions for a wide array of technologies, including:
Protein and peptide therapeutics
RNA and gene-based therapeutics
Diagnostic and prognostic tests, including genetic, gene expression, proteomic and cell-based tests for personalized medicine application
Nucleic acid sequencing and detection technologies
Recombinant protein production
Biosynthetic processes and microbial strains
Nanoparticle-based drug delivery platforms
Wound care technologies
Mark co-authored several publications in peer-reviewed journals, including the Journal of Biological Chemistry, Nucleic Acids Research, and Infection and Immunity. Mark is particularly knowledgeable with molecular biology as well as protein and nucleic acid biochemistry. He frequently writes and presents on patenting inventions in the life sciences.
Prior to joining Morgan Lewis, Mark was a partner in the corporate practice group of another international law firm.
State University of New York at Buffalo, 2000, Doctor of Philosophy, Microbiology
State University of New York at Potsdam, 1994, Bachelor of Arts, Biology
University of Pittsburgh School of Law, 2003, Juris Doctor